{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:41:03Z","timestamp":1792176063130,"version":"4.4.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":137,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.urology.2012.11.010","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T05:15:39Z","timestamp":1357190139000},"page":"491-497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis"],"prefix":"10.1016","volume":"81","author":[{"given":"Michael","family":"Kennelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Dmochowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ethans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Karsenty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Schulte-Baukloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Haag-Molkenteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2012.11.010_bib1","first-page":"692","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2012.11.010_bib2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2012.11.010_bib3","first-page":"2131","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA in patients with urinary incontinence resulting from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2012.11.010_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0090-4295(98)00454-3","article-title":"Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL)","volume":"53","author":"Patrick","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urology.2012.11.010_bib5","series-title":"Therapy with Botulinum Toxin","first-page":"93","article-title":"Immunogenicity of the neurotoxins of Clostridium botulinum","author":"Hatheway","year":"1994"},{"key":"10.1016\/j.urology.2012.11.010_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apmr.2007.02.009","article-title":"Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence","volume":"88","author":"Schurch","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.urology.2012.11.010_bib7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2012.11.010_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.urology.2012.11.010_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","article-title":"Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity","volume":"116","author":"M\u00fcller","year":"2009","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.urology.2012.11.010_bib10","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.urology.2012.11.010_bib11","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","article-title":"Basic immunological aspects of botulinum toxin therapy","volume":"19","author":"Atassi","year":"2004","journal-title":"Mov Disord"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429512013714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429512013714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:56:35Z","timestamp":1758765395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429512013714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0090429512013714"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2012.11.010","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2012.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}